<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cac212593" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Commun (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Commun (Lond)</journal-id><journal-id journal-id-type="pmc-domain-id">3437</journal-id><journal-id journal-id-type="pmc-domain">canccomms</journal-id><journal-id journal-id-type="publisher-id">CAC2</journal-id><journal-title-group><journal-title>Cancer Communications</journal-title></journal-title-group><issn pub-type="epub">2523-3548</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11492361</article-id><article-id pub-id-type="pmcid-ver">PMC11492361.1</article-id><article-id pub-id-type="pmcaid">11492361</article-id><article-id pub-id-type="pmcaiid">11492361</article-id><article-id pub-id-type="pmid">39016057</article-id><article-id pub-id-type="doi">10.1002/cac2.12593</article-id><article-id pub-id-type="publisher-id">CAC212593</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Real&#8208;world data on ALK rearrangement test in Chinese advanced non&#8208;small cell lung cancer (RATICAL): a nationwide multicenter retrospective study</article-title><alt-title alt-title-type="left-running-head">LI <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="cac212593-cr-0001" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="L">Lin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4932-6488</contrib-id><xref rid="cac212593-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cac212593-cr-0002" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="W">Wencai</given-names></name><xref rid="cac212593-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cac212593-cr-0003" contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="C">Chunyan</given-names></name><xref rid="cac212593-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cac212593-cr-0004" contrib-type="author"><name name-style="western"><surname>Xi</surname><given-names initials="Y">Yanfeng</given-names></name><xref rid="cac212593-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cac212593-cr-0005" contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="L">Lei</given-names></name><xref rid="cac212593-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cac212593-cr-0006" contrib-type="author"><name name-style="western"><surname>Ji</surname><given-names initials="Y">Yuan</given-names></name><xref rid="cac212593-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cac212593-cr-0007" contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="L">Lili</given-names></name><xref rid="cac212593-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="cac212593-cr-0008" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Ji</given-names></name><xref rid="cac212593-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="cac212593-cr-0009" contrib-type="author"><name name-style="western"><surname>Yun</surname><given-names initials="J">Jingping</given-names></name><xref rid="cac212593-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="cac212593-cr-0010" contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="G">Gang</given-names></name><xref rid="cac212593-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="cac212593-cr-0011" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yuan</given-names></name><xref rid="cac212593-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="cac212593-cr-0012" contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yueping</given-names></name><xref rid="cac212593-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="cac212593-cr-0013" contrib-type="author"><name name-style="western"><surname>Mu</surname><given-names initials="D">Dianbin</given-names></name><xref rid="cac212593-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="cac212593-cr-0014" contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="Y">Yuchen</given-names></name><xref rid="cac212593-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="cac212593-cr-0015" contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="L">Leina</given-names></name><xref rid="cac212593-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="cac212593-cr-0016" contrib-type="author"><name name-style="western"><surname>Xia</surname><given-names initials="Q">Qingxin</given-names></name><xref rid="cac212593-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="cac212593-cr-0017" contrib-type="author"><name name-style="western"><surname>Teng</surname><given-names initials="X">Xiaodong</given-names></name><xref rid="cac212593-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="cac212593-cr-0018" contrib-type="author"><name name-style="western"><surname>Che</surname><given-names initials="N">Nanying</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4179-1737</contrib-id><xref rid="cac212593-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="cac212593-cr-0019" contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="W">Wei</given-names></name><xref rid="cac212593-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="cac212593-cr-0020" contrib-type="author"><name name-style="western"><surname>Qiu</surname><given-names initials="X">Xueshan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9481-8249</contrib-id><xref rid="cac212593-aff-0019" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib id="cac212593-cr-0021" contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="C">Chao</given-names></name><xref rid="cac212593-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="cac212593-cr-0022" contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="X">Xiaochu</given-names></name><xref rid="cac212593-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="cac212593-cr-0023" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="D">Daiqiang</given-names></name><xref rid="cac212593-aff-0022" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="cac212593-cr-0024" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Z">Zhihong</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5779-9365</contrib-id><xref rid="cac212593-aff-0023" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib id="cac212593-cr-0025" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhe</given-names></name><xref rid="cac212593-aff-0024" ref-type="aff">
<sup>24</sup>
</xref></contrib><contrib id="cac212593-cr-0026" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yujun</given-names></name><xref rid="cac212593-aff-0025" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib id="cac212593-cr-0027" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zheng</given-names></name><xref rid="cac212593-aff-0026" ref-type="aff">
<sup>26</sup>
</xref></contrib><contrib id="cac212593-cr-0028" contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="L">Lingchuan</given-names></name><xref rid="cac212593-aff-0027" ref-type="aff">
<sup>27</sup>
</xref></contrib><contrib id="cac212593-cr-0029" contrib-type="author"><name name-style="western"><surname>Nie</surname><given-names initials="X">Xiu</given-names></name><xref rid="cac212593-aff-0028" ref-type="aff">
<sup>28</sup>
</xref></contrib><contrib id="cac212593-cr-0030" contrib-type="author"><name name-style="western"><surname>Geng</surname><given-names initials="J">Jingshu</given-names></name><xref rid="cac212593-aff-0029" ref-type="aff">
<sup>29</sup>
</xref></contrib><contrib id="cac212593-cr-0031" contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="J">Jianhua</given-names></name><xref rid="cac212593-aff-0030" ref-type="aff">
<sup>30</sup>
</xref></contrib><contrib id="cac212593-cr-0032" contrib-type="author" corresp="yes"><name name-style="western"><surname>Ying</surname><given-names initials="J">Jianming</given-names></name><xref rid="cac212593-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jmying@cicams.ac.cn</email></address></contrib></contrib-group><aff id="cac212593-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital</institution>
<institution>Chinese Academy of Medical Sciences and Peking Union Medical College</institution>
<city>Beijing</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the First Affiliated Hospital of Zhengzhou University</institution>
<city>Zhengzhou</city>
<named-content content-type="country-part">Henan</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Shanghai Pulmonary Hospital, School of Medicine, Tongji University</institution>
<city>Shanghai</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Cancer Hospital Affiliated to Shanxi Medical University</institution>
<institution>Shanxi Province Cancer Hospital</institution>
<institution>Shanxi Hospital Affiliated to Cancer Hospital</institution>
<institution>Chinese Academy of Medical Sciences</institution>
<city>Taiyuan</city>
<named-content content-type="country-part">Shanxi</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Zhongshan Hospital</institution>
<institution>Fudan University</institution>
<city>Shanghai</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>West China Hospital of Sichuan University</institution>
<city>Chengdu</city>
<named-content content-type="country-part">Sichuan</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Peking Union Medical College Hospital</institution>
<institution>Chinese Academy of Medical Sciences and Peking Union Medical College</institution>
<city>Beijing</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Sun Yat&#8208;sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine</institution>
<city>Guangzhou</city>
<named-content content-type="country-part">Guangdong</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Fujian Cancer Hospital</institution>
<institution>Fujian Medical University Cancer Hospital</institution>
<city>Fuzhou</city>
<named-content content-type="country-part">Fujian</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<named-content content-type="organisation-division">Department of Oncology</named-content>
<institution>Fudan University Cancer Center</institution>
<institution>Shanghai Medical College of Fudan University</institution>
<city>Shanghai</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>The Fourth Hospital of Hebei Medical University</institution>
<city>Shijiazhuang</city>
<named-content content-type="country-part">Hebei</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Shandong Cancer Hospital</institution>
<city>Jinan</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Shanghai Chest Hospital</institution>
<institution>Shanghai Jiao Tong University</institution>
<city>Shanghai</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Tianjin Medical University Cancer Institute and Hospital</institution>
<city>Tianjin</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the Affiliated Cancer Hospital of Zhengzhou University</institution>
<institution>Henan Provincial Cancer Hospital</institution>
<city>Zhengzhou</city>
<named-content content-type="country-part">Henan</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the First Affiliated Hospital, College of Medicine, Zhejiang University</institution>
<city>Hangzhou</city>
<named-content content-type="country-part">Zhejiang</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0017">
<label>
<sup>17</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Beijing Chest Hospital</institution>
<institution>Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute</institution>
<city>Beijing</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0018">
<label>
<sup>18</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)</institution>
<city>Hangzhou</city>
<named-content content-type="country-part">Zhejiang</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0019">
<label>
<sup>19</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the First Hospital of China Medical University</institution>
<city>Shenyang</city>
<named-content content-type="country-part">Liaoning</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0020">
<label>
<sup>20</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Guangdong Provincial People's Hospital</institution>
<institution>Guangdong Academy of Medical Sciences</institution>
<city>Guangzhou</city>
<named-content content-type="country-part">Guangdong</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0021">
<label>
<sup>21</sup>
</label>
<named-content content-type="organisation-division">Institute of Pathology</named-content>
<institution>Southwest Hospital</institution>
<institution>Third Military Medical University (Army Medical University)</institution>
<city>Chongqing</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0022">
<label>
<sup>22</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the Second Xiangya Hospital of Central South University</institution>
<city>Changsha</city>
<named-content content-type="country-part">Hunan</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0023">
<label>
<sup>23</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the First Affiliated Hospital of Nanjing Medical University</institution>
<city>Nanjing</city>
<named-content content-type="country-part">Jiangsu</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0024">
<label>
<sup>24</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Xijing Hospital</institution>
<institution>Fourth Military Medical University</institution>
<city>Xi'an</city>
<named-content content-type="country-part">Shaanxi</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0025">
<label>
<sup>25</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the Affiliated Hospital of Qingdao University</institution>
<city>Qingdao</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0026">
<label>
<sup>26</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Beijing Hospital, National Center of Gerontology</institution>
<city>Beijing</city>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0027">
<label>
<sup>27</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>the First Affiliated Hospital of Soochow University</institution>
<city>Suzhou</city>
<named-content content-type="country-part">Jiangsu</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0028">
<label>
<sup>28</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>
<city>Wuhan</city>
<named-content content-type="country-part">Hubei</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0029">
<label>
<sup>29</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Harbin Medical University Cancer Hospital</institution>
<city>Harbin</city>
<named-content content-type="country-part">Heilongjiang</named-content>
<country country="CN">P. R. China</country>
</aff><aff id="cac212593-aff-0030">
<label>
<sup>30</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Xiangya Hospital</institution>
<institution>Central South University</institution>
<city>Changsha</city>
<named-content content-type="country-part">Hunan</named-content>
<country country="CN">P. R. China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Jianming Ying, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Chaoyang District, Beijing, P. R. China.<break/> Email: <email>jmying@cicams.ac.cn</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>44</volume><issue seq="40">9</issue><issue-id pub-id-type="pmc-issue-id">473175</issue-id><issue-id pub-id-type="doi">10.1002/cac2.v44.9</issue-id><fpage>992</fpage><lpage>1004</lpage><history><date date-type="rev-recd"><day>16</day><month>6</month><year>2024</year></date><date date-type="received"><day>01</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>09</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>22</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-22 17:25:33.850"><day>22</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Cancer Communications</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Sun Yat&#8208;sen University Cancer Center.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAC2-44-992.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAC2-44-992.pdf"/><abstract><title>Abstract</title><sec id="cac212593-sec-0010"><title>Background</title><p>Anaplastic lymphoma kinase (<italic toggle="yes">ALK</italic>) test in advanced non&#8208;small cell lung cancer (NSCLC) can help physicians provide target therapies for patients harboring <italic toggle="yes">ALK</italic> gene rearrangement. This study aimed to investigate the real&#8208;world test patterns and positive rates of <italic toggle="yes">ALK</italic> gene rearrangements in advanced NSCLC.</p></sec><sec id="cac212593-sec-0020"><title>Methods</title><p>In this real&#8208;world study (ChiCTR2000030266), patients with advanced NSCLC who underwent an <italic toggle="yes">ALK</italic> rearrangement test in 30 medical centers in China between October 1, 2018 and December 31, 2019 were retrospectively analyzed. Interpretation training was conducted before the study was initiated. Quality controls were performed at participating centers using immunohistochemistry (IHC)&#8208;VENTANA&#8208;D5F3. The positive <italic toggle="yes">ALK</italic> gene rearrangement rate and consistency rate were calculated. The associated clinicopathological characteristics of <italic toggle="yes">ALK</italic> gene rearrangement were investigated as well.</p></sec><sec id="cac212593-sec-0030"><title>Results</title><p>The overall <italic toggle="yes">ALK</italic> gene rearrangement rate was 6.7% in 23,689 patients with advanced NSCLC and 8.2% in 17,436 patients with advanced lung adenocarcinoma. The quality control analysis of IHC&#8208;VENTANA&#8208;D5F3 revealed an intra&#8208;hospital consistency rate of 98.2% (879/895) and an inter&#8208;hospital consistency rate of 99.2% (646/651). IHC&#8208;VENTANA&#8208;D5F3 was used in 53.6%, real&#8208;time polymerase chain reaction (RT&#8208;PCR) in 25.4%, next&#8208;generation sequencing (NGS) in 18.3%, and fluorescence in&#8208;situ hybridization (FISH) in 15.9% in the adenocarcinoma subgroup. For specimens tested with multiple methods, the consistency rates confirmed by IHC&#8208;VENTANA&#8208;D5F3 were 98.0% (822/839) for FISH, 98.7% (1,222/1,238) for NGS, and 91.3% (146/160) for RT&#8208;PCR. The overall <italic toggle="yes">ALK</italic> gene rearrangement rates were higher in females, patients of &#8804; 35 years old, never smokers, tumor cellularity of &gt; 50, and metastatic specimens used for testing in the total NSCLC population and adenocarcinoma subgroup (all <italic toggle="yes">P</italic> &lt; 0.05).</p></sec><sec id="cac212593-sec-0040"><title>Conclusions</title><p>This study highlights the real&#8208;world variability and challenges of <italic toggle="yes">ALK</italic> test in advanced NSCLC, demonstrating a predominant use of IHC&#8208;VENTANA&#8208;D5F3 with high consistency and distinct clinicopathological features in <italic toggle="yes">ALK</italic>&#8208;positive patients. These findings underscore the need for a consensus on optimal test practices and support the development of refined <italic toggle="yes">ALK</italic> test strategies to enhance diagnostic accuracy and therapeutic decision&#8208;making in NSCLC.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cac212593-kwd-0001">anaplastic lymphoma kinase</kwd><kwd id="cac212593-kwd-0002">diagnosis</kwd><kwd id="cac212593-kwd-0003">gene fusion</kwd><kwd id="cac212593-kwd-0004">non&#8208;small cell lung cancer</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>CAMS Innovation Fund for Medical Sciences</funding-source><award-id>2021&#8208;1&#8208;I2M&#8208;012</award-id><award-id>2022&#8208;I2M&#8208;C&amp;T&#8208;B&#8208;078</award-id></award-group><award-group id="funding-0002"><funding-source>Beijing Hope Run Special Fund of Cancer Foundation of the People's Republic of China</funding-source><award-id>LC2019L04</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Key Research and Development Program
</institution><institution-id institution-id-type="doi">10.13039/501100012166</institution-id></institution-wrap></funding-source><award-id>2022YFC2409902</award-id></award-group><award-group id="funding-0004"><funding-source>Capital's Funds for Health Improvement and Research</funding-source><award-id>2020&#8208;2Z&#8208;4028</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="5"/><page-count count="13"/><word-count count="7674"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.9 mode:remove_FC converted:21.10.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cac212593-cit-0039"><string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Real&#8208;world data on ALK rearrangement test in Chinese advanced non&#8208;small cell lung cancer (RATICAL): a nationwide multicenter retrospective study</article-title>. <source>Cancer Commun</source>. <year>2024</year>;<volume>44</volume>:<fpage>992</fpage>&#8211;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1002/cac2.12593</pub-id><pub-id pub-id-type="pmcid">PMC11492361</pub-id><pub-id pub-id-type="pmid">39016057</pub-id></mixed-citation>
</p><fn-group><fn id="cac212593-note-0001" fn-type="equal"><p>Lin Li, Wencai Li, Chunyan Wu, Yanfeng Xi, Lei Guo, Yuan Ji, Lili Jiang, Ji Li, Jingping Yun, Gang Chen, and Yuan Li contributed equally to this work as co&#8208;first authors.</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="cac212593-dl-0001"><title>Abbreviations</title><def-item><term>
<italic toggle="yes">ALK</italic>
</term><def><p>anaplastic lymphoma kinase</p></def></def-item><def-item><term>EMR</term><def><p>electronic medical record</p></def></def-item><def-item><term>FISH</term><def><p>fluorescence in&#8208;situ hybridization</p></def></def-item><def-item><term>IHC</term><def><p>immunohistochemistry</p></def></def-item><def-item><term>NGS</term><def><p>next&#8208;generation sequencing</p></def></def-item><def-item><term>NSCLC</term><def><p>non&#8208;small cell lung cancer</p></def></def-item><def-item><term>NMPA</term><def><p>national medical products administration;</p></def></def-item><def-item><term>RT&#8208;PCR</term><def><p>real&#8208;time polymerase chain reaction</p></def></def-item></def-list><sec id="cac212593-sec-0050"><label>1</label><title>BACKGROUND</title><p>Primary lung cancer (hereafter refers to as lung cancer) that begins in the lungs is one of the most common malignant tumors in China [<xref rid="cac212593-bib-0001" ref-type="bibr">1</xref>] and worldwide [<xref rid="cac212593-bib-0002" ref-type="bibr">2</xref>]. According to the World Health Organization, the Global Cancer Observatory (GLOBOCAN) 2020 and the National Cancer Center database, 815,600 new lung cancer patients and 714,700 deaths caused by lung cancer were seen in 2020 in China, ranking first among all malignant tumors causing mortality [<xref rid="cac212593-bib-0003" ref-type="bibr">3</xref>]. More than 80% of lung cancer patients have non&#8208;small cell lung cancer (NSCLC) [<xref rid="cac212593-bib-0001" ref-type="bibr">1</xref>, <xref rid="cac212593-bib-0002" ref-type="bibr">2</xref>].</p><p>In the past decade, discovering predictive biomarkers has paved the way for new treatment opportunities using targeted therapy and immunotherapy in the NSCLC [<xref rid="cac212593-bib-0004" ref-type="bibr">4</xref>, <xref rid="cac212593-bib-0005" ref-type="bibr">5</xref>, <xref rid="cac212593-bib-0006" ref-type="bibr">6</xref>]. Anaplastic lymphoma kinase (<italic toggle="yes">ALK</italic>) gene rearrangement is the third most common driving mutation in the development of NSCLC after mutations in epidermal growth factor receptor (<italic toggle="yes">EGFR</italic>) and Kirsten rat sarcoma viral oncogene homolog (<italic toggle="yes">KRAS</italic>) [<xref rid="cac212593-bib-0007" ref-type="bibr">7</xref>, <xref rid="cac212593-bib-0008" ref-type="bibr">8</xref>], and previous studies from China [<xref rid="cac212593-bib-0009" ref-type="bibr">9</xref>] and America [<xref rid="cac212593-bib-0010" ref-type="bibr">10</xref>] showing that <italic toggle="yes">ALK</italic> gene rearrangement occurs in 3%&#8208;7% of NSCLC cases, with a high incidence among adenocarcinoma and non&#8208;smoking patients. The echinoderm microtubule&#8208;associated protein&#8208;like 4 (<italic toggle="yes">EML4</italic>)<italic toggle="yes">&#8208;ALK</italic> fusion is the primary type of <italic toggle="yes">ALK</italic> rearrangement. In addition to <italic toggle="yes">EML4</italic>, other genes fused with the <italic toggle="yes">ALK</italic> gene in lung cancer include kinesin family 5B (<italic toggle="yes">KIF5B</italic>), kinesin light chain (<italic toggle="yes">KLC</italic>), trafficking from ER to golgi regulator (<italic toggle="yes">TFG</italic>), and others [<xref rid="cac212593-bib-0011" ref-type="bibr">11</xref>, <xref rid="cac212593-bib-0012" ref-type="bibr">12</xref>, <xref rid="cac212593-bib-0013" ref-type="bibr">13</xref>].</p><p>Currently, the molecular target drugs in the market (e.g., crizotinib and alectinib) for lung cancer with <italic toggle="yes">ALK</italic> gene rearrangement and other genetic variations have significantly improved the patients' outcome [<xref rid="cac212593-bib-0014" ref-type="bibr">14</xref>, <xref rid="cac212593-bib-0015" ref-type="bibr">15</xref>], even for squamous cell carcinoma [<xref rid="cac212593-bib-0016" ref-type="bibr">16</xref>]. Therefore, detecting the <italic toggle="yes">ALK</italic> gene rearrangements in an accurate, standardized, and cost&#8208;effective manner is critical for selecting drugs to manage lung cancer. Presently, China's National Medical Products Administration (NMPA) has approved <italic toggle="yes">ALK</italic> gene rearrangement diagnostics in four technical platforms, such as immunohistochemistry (IHC)&#8208;VENTANA&#8259;D5F3, fluorescence in&#8208;situ hybridization (FISH), real&#8208;time polymerase chain reaction (RT&#8208;PCR), and next&#8208;generation sequencing (NGS). The FISH technique requires a small amount of tumor sample, but the procedure is technologically demanding and has atypical negative signals. RT&#8208;PCR has high specificity and sensitivity but can only detect currently known variants. IHC&#8208;VENTANA&#8208;D5F3 is simple, inexpensive, and can be performed in almost all locations, but the criteria for positive response are not applicable in all cases, leading to ambiguous results and the need for other platforms. NGS can detect most variants, but it is expensive and requires a test run. To address this situation, experts from the RATICAL study and the Chinese Society of Clinical Oncology issued guidelines for the <italic toggle="yes">ALK</italic> fusion test in NSCLC in 2021 to adopt in clinical practice [<xref rid="cac212593-bib-0017" ref-type="bibr">17</xref>].</p><p>However, selecting an appropriate diagnostic method with good quality control for detecting <italic toggle="yes">ALK</italic> rearrangements has been challenging, impacting the clinical benefit. To gain knowledge on the current status and quality control of <italic toggle="yes">ALK</italic> gene test in lung adenocarcinoma, we planned a nationwide multicenter clinical study (the RATICAL study) including NSCLC patients who underwent <italic toggle="yes">ALK</italic> gene test from 30 medical centers. This study aimed to investigate the real&#8208;world test patterns of <italic toggle="yes">ALK</italic> gene rearrangements in advanced NSCLC, including the detection methods and quality control, and to investigate the positive rates, the associated clinicopathological characteristics, and the presence of other mutations.</p></sec><sec id="cac212593-sec-0060"><label>2</label><title>METHODS</title><sec id="cac212593-sec-0070"><label>2.1</label><title>Study design and participants</title><p>In this real&#8208;world data on ALK Test In Chinese Advanced Lung cancer (i.e., the RATICAL study) (registered at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chictr.org.cn/" ext-link-type="uri">https://www.chictr.org.cn/</ext-link>, with identifier ChiCTR2000030266) conducted across 30 nationwide medical centers, data from patients with advanced NSCLC who underwent an <italic toggle="yes">ALK</italic> test between October 1, 2018 and December 31, 2019 were retrospectively collected (28 centers provided data). This retrospective study was approved by the Ethics Committee of the Cancer Hospital of the Chinese Academy of Medical Sciences (approval no. 2018091013463902) and reported to the Ethics Committee of all study centers.</p><p>The inclusion criteria were 1) patients histologically or cytologically diagnosed with NSCLC and 2) patients with advanced NSCLC (IIIB, IIIC, or IV), as defined by the American Joint Committee on Cancer Staging Manual, 8th edition, who underwent ALK test. The exclusion criteria were 1) patients who went for a third&#8208;party <italic toggle="yes">ALK</italic> assay outside the participating hospitals, 2) patients who underwent <italic toggle="yes">ALK</italic> test using different types of specimens, where each sample type used a different test method, 3) patients with no tumor cells in hydrothorax, as the absence of tumor cells may compromise the reliability of <italic toggle="yes">ALK</italic> test results, 4) patients who had the RT&#8208;PCR detection method with targeted multiple genes/locations but no <italic toggle="yes">ALK</italic> gene rearrangements, 5) patients with missing information such as age, sex or <italic toggle="yes">ALK</italic> results, and 6) patients who did not have conclusive <italic toggle="yes">ALK</italic> test results that could be analyzed.</p></sec><sec id="cac212593-sec-0080"><label>2.2</label><title>Data collection</title><p>The baseline information of the patients, such as age, sex, smoking status (current, past, or never), type of cancer (adenocarcinoma, squamous, or others), tumor site (non&#8208;metastatic or metastatic), and cancer stage, was collected from the electronic medical record (EMR) system.</p><p>This study was a real&#8208;world study. Therefore, <italic toggle="yes">ALK</italic> test was based on the clinical reality of each participating hospital. In order to detect <italic toggle="yes">ALK</italic> and other driver genes, particulars on the type of sample tested (samples from tissue, body fluid, and cells), the test methods (FISH, IHC, NGS, and RT&#8208;PCR), and the results (positive or negative) were collected. Specifically, for IHC testing, data regarding the use of different antibody variants such as 5A4, and 1A4 were also gathered. Information on other driver genes or biomarkers was also recorded, including B&#8208;Raf proto&#8208;oncogene serine/threonine&#8208;protein kinase (<italic toggle="yes">BRAF</italic>), human epidermal growth factor receptor 2 (<italic toggle="yes">ERBB2</italic>)<italic toggle="yes">, KRAS</italic>, mesenchymal&#8208;epithelial transition factor (<italic toggle="yes">MET</italic>), neuroblastoma rat sarcoma viral oncogene homolog (<italic toggle="yes">NRAS</italic>), rearranged during transfection (<italic toggle="yes">RET</italic>), c&#8208;ros oncogene 1 (<italic toggle="yes">ROS1</italic>), and programmed death ligand&#8208;1 (PD&#8208;L1).</p></sec><sec id="cac212593-sec-0090"><label>2.3</label><title>Quality control</title><p>Supplementary Figure <xref rid="cac212593-supitem-0001" ref-type="supplementary-material">S1</xref> presents the technological workflow. We included 109 cases of lung adenocarcinoma diagnosed using the automated <italic toggle="yes">ALK</italic> IHC&#8208;VENTANA&#8208;D5F3 test for the analysis of consistency between local pathologists who reported initial results at each participating cancer and study group pathologists who initiated this RATICAL study. These cases included 49 positive and 60 negative diagnoses, all re&#8208;assessed by 31 pathologists from the RATICAL study group (including 13 chief pathologists, 11 associate chief pathologists, and 7 attending pathologists). The concordance rate achieved was 98.2%, with only two cases showing inconsistency between local pathologists and pathologists from the RATICAL study group, as previously reported [<xref rid="cac212593-bib-0018" ref-type="bibr">18</xref>].</p><p>To further ensure the accuracy of the IHC&#8208;VENTANA&#8208;D5F3 results, an intra&#8208;hospital quality control procedure was implemented across 22 participating hospitals. In addition to the intra&#8208;hospital quality control, the inter&#8208;hospital concordance rate of IHC&#8208;VENTANA&#8208;D5F3 was assessed by evaluating 10 ALK gene rearrangement cases and 20 ALK&#8208;negative cases across different hospitals within the same city or region, using multifocal microscopes to ensure the reproducibility of results across nearby facilities. For samples initially tested using RT&#8208;PCR or NGS, a sample of cases (both positive and negative) that had results available for <italic toggle="yes">ALK</italic> test through IHC, RT&#8208;PCR, or NGS were selected for inter&#8208;hospital consistency analysis. Each of 11 hospitals randomly selected cases in a recommended ratio of RT&#8208;PCR: NGS = 6:4, or 10 RT&#8208;PCR cases if NGS was not available. These samples were sent to the central laboratory at Department of Pathology at the Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, China for retesting using <italic toggle="yes">ALK</italic> IHC&#8208;VENTANA&#8208;D5F3 to compare and validate the findings across different diagnostic platforms.</p></sec><sec id="cac212593-sec-0100"><label>2.4</label><title>Statistical analysis</title><p>The continuous data were tested for normal distribution using the Shapiro&#8208;Wilk method. Continuous data with a normal distribution are expressed as mean &#177; standard deviation; otherwise, they are expressed as median (upper and lower quartiles). Categorical data are expressed as percentages, and the chi&#8208;square test was used to compare groups. The differences were statistically significant when the <italic toggle="yes">P</italic> value was &lt;0.05. R programming language version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analyses.</p></sec></sec><sec id="cac212593-sec-0110"><label>3</label><title>RESULTS</title><sec id="cac212593-sec-0120"><label>3.1</label><title>Quality control outcomes</title><p>Using the IHC&#8208;VENTANA&#8208;D5F3 protocol, nationwide clinical centers tested 895 cases for intra&#8208;hospital quality control. Among these, 288 were initially reported as positive, 601 were negative, and 6 were classified as suspiciously positive. Sixteen patients exhibited inconsistent results compared to initial evaluations, resulting in an overall concordance rate of 98.2%. The inconsistencies were primarily due to several factors: squamous carcinoma with inconclusive IHC results, positive control failure, incorrect interpretations, and excessive non&#8208;specific background staining.</p><p>In the inter&#8208;hospital consistency analysis of IHC&#8208;VENTANA&#8208;D5F3, a total of 651 samples (216 with positive <italic toggle="yes">ALK</italic> gene rearrangement and 435 samples without) were tested. Upon retesting these samples in the central laboratory (Department of Pathology at the Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, China), 5 of these results were inconsistent with the initial findings, with a concordance rate of 99.2%. These inconsistencies were primarily attributed to being misclassified as positive due to intracytoplasmic patch&#8208;like staining in squamous carcinoma, weak staining, and positive control failure.</p><p>In order to determine quality control using other protocols, 119 samples were retested, and 2 were not included in the analyses due to the absence of tumor cells on received IHC&#8208;VENTANA&#8208;D5F3 slides. Eight of the 117 patients had inconsistent results compared with the initial results, reaching a concordance rate of 93.2%. Among these inconsistencies, 5 cases initially diagnosed as positive by RT&#8208;PCR at local laboratories at each participating center were tested negative by IHC&#8208;VENTANA&#8208;D5F3 at the central laboratory. Upon retesting at the local laboratories, 3 of these cases were confirmed as negative by both IHC&#8208;VENTANA&#8208;D5F3 and 2 by FISH, suggesting initial false positives. One case, initially diagnosed as weakly positive by IHC&#8208;VENTANA&#8208;D5F3, showed positive results by FISH upon retesting, and another case had no tumor cells available at the time of retesting. One positive case by initial FISH was tested negative by IHC&#8208;VENTANA&#8208;D5F3 at the center laboratory, and no tumor cells were found upon retesting at the local laboratories. Two cases were were tested negative by FISH at local centers but tested positive by IHC&#8208;VENTANA&#8208;D5F3 at the center laboratory; both were confirmed as positive upon retesting at the local laboratories at each participating center.</p></sec><sec id="cac212593-sec-0130"><label>3.2</label><title>Patient characteristics</title><p>A total of 25,616 patients were screened, 187 patients were excluded due to missing data and unclear <italic toggle="yes">ALK</italic> gene rearrangement results, and 1,740 patients were excluded because they had early&#8208;stage NSCLC. Therefore, 23,689 samples were analyzed, including 17,436 patients with adenocarcinoma (Figure&#160;<xref rid="cac212593-fig-0001" ref-type="fig">1</xref>). In the present study, 19.6% of patients were tested with samples obtained from metastatic foci and 81.7% of <italic toggle="yes">ALK</italic> tests were performed on histological samples in clinical practice, followed by cytological samples (15.9%). The overall <italic toggle="yes">ALK</italic> gene rearrangement rate was 6.7% in advanced NSCLC. <italic toggle="yes">ALK</italic> rearrangements were more common in adenocarcinoma (8.2%) than in squamous (1.5%) and other types (4.2%) (<italic toggle="yes">P</italic> &lt; 0.001). The characteristics of the patients with NSCLC and adenocarcinoma are shown in Table&#160;<xref rid="cac212593-tbl-0001" ref-type="table">1</xref>.</p><fig position="float" fig-type="FIGURE" id="cac212593-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flow chart of patients screening, inclusion and exclusion. * Some specimens were tested with multiple methods. Abbreviations: <italic toggle="yes">ALK</italic>, Anaplastic lymphoma kinase; FISH: fluorescence in&#8208;situ hybridization; NGS, next&#8208;generation sequencing; NSCLC, non&#8208;small cell lung cancer; RT&#8208;PCR, real&#8208;time polymerase chain reaction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CAC2-44-992-g001.jpg"/></fig><table-wrap position="float" id="cac212593-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Clinicopathological characteristics of the patients with advanced NSCLC and advanced adenocarcinoma</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Advanced NSCLC (<italic toggle="yes">n</italic> = 23,689)</th><th align="left" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Advanced adenocarcinoma (<italic toggle="yes">n</italic> = 17,436)</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">ALK</italic>&#8208;positive</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">ALK</italic>&#8208;negative</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">ALK</italic>&#8208;positive</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">ALK</italic>&#8208;negative</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">1,590 (6.7)</td><td align="char" rowspan="1" colspan="1">22,099 (93.3)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">1,422 (8.2)</td><td align="char" rowspan="1" colspan="1">16,014 (91.8)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">757 (5.2)</td><td align="char" rowspan="1" colspan="1">13,725 (94.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">658 (7.1)</td><td align="char" rowspan="1" colspan="1">8,669 (92.9)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">833 (9.0)</td><td align="char" rowspan="1" colspan="1">8,374 (91.0)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">764 (9.4)</td><td align="char" rowspan="1" colspan="1">7,345 (90.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#8804; 35</td><td align="char" rowspan="1" colspan="1">110 (31.9)</td><td align="char" rowspan="1" colspan="1">235 (68.1)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">102 (34.6)</td><td align="char" rowspan="1" colspan="1">193 (65.4)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">36&#8208;65</td><td align="char" rowspan="1" colspan="1">1,217 (8.4)</td><td align="char" rowspan="1" colspan="1">13,320 (91.6)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">1,090 (9.8)</td><td align="char" rowspan="1" colspan="1">10,001 (90.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&gt; 65</td><td align="char" rowspan="1" colspan="1">263 (3.0)</td><td align="char" rowspan="1" colspan="1">8,544 (97.0)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">230 (3.8)</td><td align="char" rowspan="1" colspan="1">5,820 (96.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smokers, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Current</td><td align="char" rowspan="1" colspan="1">280 (4.2)</td><td align="char" rowspan="1" colspan="1">6,381 (95.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">238 (5.6)</td><td align="char" rowspan="1" colspan="1">3,985 (94.4)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Never</td><td align="char" rowspan="1" colspan="1">853 (8.3)</td><td align="char" rowspan="1" colspan="1">9,439 (91.7)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">782 (9.3)</td><td align="char" rowspan="1" colspan="1">7,650 (90.7)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Unknown</td><td align="char" rowspan="1" colspan="1">457 (6.8)</td><td align="char" rowspan="1" colspan="1">6,279 (93.2)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">402 (8.4)</td><td align="char" rowspan="1" colspan="1">4,379 (91.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor cellularity, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">0.024</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">0.033</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#8804; 30</td><td align="char" rowspan="1" colspan="1">227 (6.7)</td><td align="char" rowspan="1" colspan="1">3,181 (93.3)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">215 (7.9)</td><td align="char" rowspan="1" colspan="1">2,494 (92.1)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">31&#8208;50</td><td align="char" rowspan="1" colspan="1">214 (7.2)</td><td align="char" rowspan="1" colspan="1">2,756 (92.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">196 (8.3)</td><td align="char" rowspan="1" colspan="1">2,155 (91.7)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&gt; 50</td><td align="char" rowspan="1" colspan="1">325 (8.3)</td><td align="char" rowspan="1" colspan="1">3,590 (91.7)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">295 (9.8)</td><td align="char" rowspan="1" colspan="1">2,720 (90.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor location, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Right upper lobe</td><td align="char" rowspan="1" colspan="1">173 (4.4)</td><td align="char" rowspan="1" colspan="1">3,760 (95.6)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">155 (5.2)</td><td align="char" rowspan="1" colspan="1">2,807 (94.8)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Right lower lobe</td><td align="char" rowspan="1" colspan="1">196 (7.8)</td><td align="char" rowspan="1" colspan="1">2,317 (92.2)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">177 (9.5)</td><td align="char" rowspan="1" colspan="1">1,696 (90.5)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Right middle lobe</td><td align="char" rowspan="1" colspan="1">132 (9.8)</td><td align="char" rowspan="1" colspan="1">1,213 (90.2)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">121 (11.9)</td><td align="char" rowspan="1" colspan="1">898 (88.1)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Left upper lobe</td><td align="char" rowspan="1" colspan="1">226 (6.8)</td><td align="char" rowspan="1" colspan="1">3,103 (93.2)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">204 (8.4)</td><td align="char" rowspan="1" colspan="1">2,230 (91.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Left lower lobe</td><td align="char" rowspan="1" colspan="1">179 (8.7)</td><td align="char" rowspan="1" colspan="1">1,887 (91.3)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">160 (10.5)</td><td align="char" rowspan="1" colspan="1">1,371 (89.5)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other</td><td align="char" rowspan="1" colspan="1">684 (6.5)</td><td align="char" rowspan="1" colspan="1">9,819 (93.5)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">605 (7.9)</td><td align="char" rowspan="1" colspan="1">7,012 (92.1)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sampling lesion, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Primary</td><td align="char" rowspan="1" colspan="1">1,043 (5.6)</td><td align="char" rowspan="1" colspan="1">17,443 (94.4)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">934 (7.1)</td><td align="char" rowspan="1" colspan="1">12,247 (92.9)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Metastatic</td><td align="char" rowspan="1" colspan="1">498 (10.7)</td><td align="char" rowspan="1" colspan="1">4,151 (89.3)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">452 (11.5)</td><td align="char" rowspan="1" colspan="1">3,469 (88.5)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Unknown</td><td align="char" rowspan="1" colspan="1">49 (8.8)</td><td align="char" rowspan="1" colspan="1">505 (91.2)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">36 (10.8)</td><td align="char" rowspan="1" colspan="1">298 (89.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pathology, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="char" rowspan="1" colspan="1">1,422 (8.2)</td><td align="char" rowspan="1" colspan="1">16,014 (91.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Squamous</td><td align="char" rowspan="1" colspan="1">50 (1.5)</td><td align="char" rowspan="1" colspan="1">3,392 (98.5)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other</td><td align="char" rowspan="1" colspan="1">118 (4.2)</td><td align="char" rowspan="1" colspan="1">2,693 (95.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TNM stage, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">0.003</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">III</td><td align="char" rowspan="1" colspan="1">331 (5.7)</td><td align="char" rowspan="1" colspan="1">5,512 (94.3)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">293 (7.8)</td><td align="char" rowspan="1" colspan="1">3,463 (92.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">IV</td><td align="char" rowspan="1" colspan="1">874 (6.9)</td><td align="char" rowspan="1" colspan="1">11,752 (93.1)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">780 (7.8)</td><td align="char" rowspan="1" colspan="1">9,240 (92.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Unknown</td><td align="char" rowspan="1" colspan="1">385 (7.4)</td><td align="char" rowspan="1" colspan="1">4,835 (92.6)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">349 (9.5)</td><td align="char" rowspan="1" colspan="1">3,311 (90.5)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sample type, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">0.003</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">0.003</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Histological specimen</td><td align="char" rowspan="1" colspan="1">1,340 (6.9)</td><td align="char" rowspan="1" colspan="1">18,017 (93.1)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">1,204 (8.3)</td><td align="char" rowspan="1" colspan="1">13,224 (91.7)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cytological specimen</td><td align="char" rowspan="1" colspan="1">226 (6.0)</td><td align="char" rowspan="1" colspan="1">3,536 (94.0)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">196 (7.7)</td><td align="char" rowspan="1" colspan="1">2,337 (92.3)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Body fluid specimens</td><td align="char" rowspan="1" colspan="1">15 (3.2)</td><td align="char" rowspan="1" colspan="1">448 (96.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">13 (3.4)</td><td align="char" rowspan="1" colspan="1">375 (96.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other</td><td align="char" rowspan="1" colspan="1">9 (8.4)</td><td align="char" rowspan="1" colspan="1">98 (91.6)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">9 (10.3)</td><td align="char" rowspan="1" colspan="1">78 (89.7)</td><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cac212593-tbl1-note-0001"><p>Abbreviation: NSCLC, non&#8208;small cell lung cancer.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>In the total NSCLC patients, the overall <italic toggle="yes">ALK</italic> gene rearrangement rates were higher in females (<italic toggle="yes">P</italic> &lt; 0.001), &#8804; 35 years of age (<italic toggle="yes">P</italic> &lt; 0.001), never smokers (<italic toggle="yes">P</italic> &lt; 0.001), with tumor cellularity of &gt;50 (<italic toggle="yes">P</italic> = 0.024), samples from metastatic tumors (<italic toggle="yes">P</italic> &lt; 0.001), and diagnosed using histological specimens (<italic toggle="yes">P</italic> = 0.003), similarly in the adenocarcinoma subgroup (Table&#160;<xref rid="cac212593-tbl-0001" ref-type="table">1</xref>). Supplementary Figure <xref rid="cac212593-supitem-0001" ref-type="supplementary-material">S2</xref> shows the distribution of non&#8208;adenocarcinoma cases from the participating centers.</p></sec><sec id="cac212593-sec-0140"><label>3.3</label><title>Frequency and positive <italic toggle="yes">ALK</italic> gene rearrangement rate by different detection methods</title><p>Table&#160;<xref rid="cac212593-tbl-0002" ref-type="table">2</xref> presents the data of <italic toggle="yes">ALK</italic> gene rearrangement determined by different detection methods in the adenocarcinoma subgroup. The most common detection method was IHC&#8208;VENTANA&#8208;D5F3 (53.6%), followed by RT&#8208;PCR (25.4%), NGS (18.3%, all DNA&#8208;based), and FISH (15.9%). The frequency of detection methods in each center differed (Supplementary Table <xref rid="cac212593-supitem-0001" ref-type="supplementary-material">S1</xref>). In the meantime, the <italic toggle="yes">ALK</italic> gene rearrangement rates determined by RT&#8208;PCR, NGS, and FISH were 9.1%, 8.2%, and 5.3%, respectively. The <italic toggle="yes">ALK</italic> gene rearrangement rate varied from 4.3% to 11.0% in advanced NSCLC and from 4.7% to 11.9% in advanced adenocarcinoma across hospitals (Supplementary Table <xref rid="cac212593-supitem-0001" ref-type="supplementary-material">S2</xref>). For specimens tested with multiple methods, the agreement of detection was high (&gt;95%) among the methods, except between IHC&#8208;VENTANA&#8208;D5F3 and PCR (91.3%), NGS and PCR (90.9%), and IHC&#8208;5A4 and IHC&#8208;VENTANA&#8208;D5F3 (75.0%) (Table&#160;<xref rid="cac212593-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="cac212593-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>
<italic toggle="yes">ALK</italic> gene rearrangement determined by different detection methods in 17,436 patients with advanced adenocarcinoma.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Advanced adenocarcinoma, n (%)</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Detection method</th><th align="left" rowspan="1" colspan="1">Overall<xref rid="cac212593-tbl2-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">ALK</italic>&#8208;positive</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">ALK</italic>&#8208;negative</th><th align="left" rowspan="1" colspan="1">Uncertain</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IHC&#8208;VENTANA&#8208;D5F3</td><td align="char" rowspan="1" colspan="1">9,353 (53.6)</td><td align="char" rowspan="1" colspan="1">847 (9.1)</td><td align="char" rowspan="1" colspan="1">8,494 (90.8)</td><td align="char" rowspan="1" colspan="1">12 (0.1)<xref rid="cac212593-tbl2-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">IHC&#8208;1A4</td><td align="char" rowspan="1" colspan="1">45 (0.3)</td><td align="char" rowspan="1" colspan="1">3 (6.7)</td><td align="char" rowspan="1" colspan="1">41 (91.1)</td><td align="char" rowspan="1" colspan="1">1 (2.2)<xref rid="cac212593-tbl2-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">IHC&#8208;5A4</td><td align="char" rowspan="1" colspan="1">52 (0.3)</td><td align="char" rowspan="1" colspan="1">2 (3.8)</td><td align="char" rowspan="1" colspan="1">49 (94.2)</td><td align="char" rowspan="1" colspan="1">1 (1.9)<xref rid="cac212593-tbl2-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">RT&#8208;PCR</td><td align="char" rowspan="1" colspan="1">4,430 (25.4)</td><td align="char" rowspan="1" colspan="1">404 (9.1)</td><td align="char" rowspan="1" colspan="1">4,026 (90.9)</td><td align="char" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">NGS</td><td align="char" rowspan="1" colspan="1">3,198 (18.3)</td><td align="char" rowspan="1" colspan="1">261 (8.2)</td><td align="char" rowspan="1" colspan="1">2,937 (91.8)</td><td align="char" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">FISH</td><td align="char" rowspan="1" colspan="1">2,772 (15.9)</td><td align="char" rowspan="1" colspan="1">146 (5.3)</td><td align="char" rowspan="1" colspan="1">2,626 (94.7)</td><td align="char" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="cac212593-tbl2-note-0003"><p>Abbreviations: FISH, fluorescence in&#8208;situ hybridization; IHC, Immunohistochemistry; NGS, next&#8208;generation sequencing; RT&#8208;PCR, real&#8208;time polymerase chain reaction.</p></fn><fn id="cac212593-tbl2-note-0001"><label>
<sup>a</sup>
</label><p>The percentage represents the proportion of patients using each method among 17,436 patients.</p></fn><fn id="cac212593-tbl2-note-0002"><label>
<sup>b</sup>
</label><p>The 12 samples with uncertain results using IHC&#8208;VENTANA&#8208;D5F3 were confirmed using FISH (11 negative and 1 positive); 1 sample with uncertain result using IHC&#8208;1A4 and 1 using IHC&#8208;5A4 were confirmed using FISH (both negative).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="cac212593-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Agreement between different detection methods in detecting adenocarcinoma.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Detection methods</th><th align="left" rowspan="1" colspan="1">IHC&#8208;D5F3</th><th align="left" rowspan="1" colspan="1">FISH</th><th align="left" rowspan="1" colspan="1">NGS</th><th align="left" rowspan="1" colspan="1">PCR</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">
<bold>IHC</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1A4</bold>
</td><td align="left" rowspan="1" colspan="1">100% (7/7)</td><td align="left" rowspan="1" colspan="1">96.9% (31/32)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>5A4</bold>
</td><td align="left" rowspan="1" colspan="1">75.0% (3/4)</td><td align="left" rowspan="1" colspan="1">96.6% (28/29)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IHC&#8208;VENTANA&#8208;D5F3</bold>
</td><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">98.0% (822/839)</td><td align="left" rowspan="1" colspan="1">98.7% (1,222/1,238)</td><td align="left" rowspan="1" colspan="1">91.3% (146/160)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>FISH</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">96.1% (123/128)</td><td align="left" rowspan="1" colspan="1">100% (1/1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>NGS</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8212;</td><td align="left" rowspan="1" colspan="1">90.9% (20/22)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>PCR</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot><fn id="cac212593-tbl3-note-0001"><p>Abbreviations: FISH, fluorescence in&#8208;situ hybridization; IHC, Immunohistochemistry; NGS, next&#8208;generation sequencing; PCR, polymerase chain reaction.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="cac212593-sec-0150"><label>3.4</label><title>Common mutations in patients with advanced NSCLC and adenocarcinoma</title><p>As shown in Table&#160;<xref rid="cac212593-tbl-0004" ref-type="table">4</xref>, the positive rates of <italic toggle="yes">EGFR</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">ERBB2</italic>, <italic toggle="yes">ROS1</italic>, <italic toggle="yes">MET</italic>, <italic toggle="yes">BRAF</italic>, and <italic toggle="yes">RET</italic> gene alterations in patients with advanced NSCLC were 44.9% (5,730/12,763), 9.0% (912/10,181), 2.2% (177/7,933), 2.0% (276/13,748), 1.8% (143/7,733), 1.3% (134/9,978), and 1.2% (104/8,932), respectively.</p><table-wrap position="float" id="cac212593-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Common mutations in patients with advanced NSCLC and advanced adenocarcinoma.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Advanced NSCLC</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Advanced adenocarcinoma</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Genotype</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" rowspan="1" colspan="1">
<p>
<italic toggle="yes">ALK&#8208;</italic>positive</p>
<p>
<italic toggle="yes">n</italic> (%)</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" rowspan="1" colspan="1">
<p>
<italic toggle="yes">ALK</italic>&#8208;positive</p>
<p>
<italic toggle="yes">n</italic> (%)</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BRAF</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">134</td><td align="char" rowspan="1" colspan="1">1 (0.7)</td><td align="char" rowspan="1" colspan="1">113</td><td align="char" rowspan="1" colspan="1">1 (0.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">9,844</td><td align="char" rowspan="1" colspan="1">692 (7.0)</td><td align="char" rowspan="1" colspan="1">7,467</td><td align="char" rowspan="1" colspan="1">608 (8.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">ERBB2</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">177</td><td align="char" rowspan="1" colspan="1">3 (1.7)</td><td align="char" rowspan="1" colspan="1">156</td><td align="char" rowspan="1" colspan="1">3 (1.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">7,756</td><td align="char" rowspan="1" colspan="1">487 (6.3)</td><td align="char" rowspan="1" colspan="1">5,838</td><td align="char" rowspan="1" colspan="1">431 (7.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">EGFR</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">5,730</td><td align="char" rowspan="1" colspan="1">32 (0.6)</td><td align="char" rowspan="1" colspan="1">5,309</td><td align="char" rowspan="1" colspan="1">30 (0.6)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">7,033</td><td align="char" rowspan="1" colspan="1">917 (13.0)</td><td align="char" rowspan="1" colspan="1">4,769</td><td align="char" rowspan="1" colspan="1">820 (17.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">KRAS</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">912</td><td align="char" rowspan="1" colspan="1">10 (1.1)</td><td align="char" rowspan="1" colspan="1">745</td><td align="char" rowspan="1" colspan="1">9 (1.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">9,269</td><td align="char" rowspan="1" colspan="1">707 (7.6)</td><td align="char" rowspan="1" colspan="1">7,011</td><td align="char" rowspan="1" colspan="1">624 (8.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">MET</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">143</td><td align="char" rowspan="1" colspan="1">3 (2.1)</td><td align="char" rowspan="1" colspan="1">122</td><td align="char" rowspan="1" colspan="1">3 (2.5)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">7,590</td><td align="char" rowspan="1" colspan="1">488 (6.4)</td><td align="char" rowspan="1" colspan="1">5,752</td><td align="char" rowspan="1" colspan="1">434 (7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">RET</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">104</td><td align="char" rowspan="1" colspan="1">2 (1.9)</td><td align="char" rowspan="1" colspan="1">92</td><td align="char" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">8,828</td><td align="char" rowspan="1" colspan="1">540 (6.1)</td><td align="char" rowspan="1" colspan="1">6,731</td><td align="char" rowspan="1" colspan="1">478 (7.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">ROS1</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">276</td><td align="char" rowspan="1" colspan="1">10 (3.6)</td><td align="char" rowspan="1" colspan="1">234</td><td align="char" rowspan="1" colspan="1">10 (4.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">13,472</td><td align="char" rowspan="1" colspan="1">852 (6.3)</td><td align="char" rowspan="1" colspan="1">9,827</td><td align="char" rowspan="1" colspan="1">755 (7.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">PD&#8208;L1 [22C3]</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">779</td><td align="char" rowspan="1" colspan="1">75 (9.6)</td><td align="char" rowspan="1" colspan="1">597</td><td align="char" rowspan="1" colspan="1">70 (11.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">1,042</td><td align="char" rowspan="1" colspan="1">60 (5.8)</td><td align="char" rowspan="1" colspan="1">822</td><td align="char" rowspan="1" colspan="1">56 (6.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">PD&#8208;L1 [288]</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">510</td><td align="char" rowspan="1" colspan="1">24 (4.7)</td><td align="char" rowspan="1" colspan="1">348</td><td align="char" rowspan="1" colspan="1">19 (5.5)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">824</td><td align="char" rowspan="1" colspan="1">34 (4.1)</td><td align="char" rowspan="1" colspan="1">672</td><td align="char" rowspan="1" colspan="1">28 (4.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">PD&#8208;L1 [SP142]</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">1,009</td><td align="char" rowspan="1" colspan="1">42 (4.2)</td><td align="char" rowspan="1" colspan="1">602</td><td align="char" rowspan="1" colspan="1">35 (5.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">1,709</td><td align="char" rowspan="1" colspan="1">83 (4.9)</td><td align="char" rowspan="1" colspan="1">1,292</td><td align="char" rowspan="1" colspan="1">94 (7.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">PD&#8208;L1 [SP263]</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Positive</td><td align="char" rowspan="1" colspan="1">186</td><td align="char" rowspan="1" colspan="1">21 (11.3)</td><td align="char" rowspan="1" colspan="1">129</td><td align="char" rowspan="1" colspan="1">18 (14.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Negative</td><td align="char" rowspan="1" colspan="1">120</td><td align="char" rowspan="1" colspan="1">5 (4.2)</td><td align="char" rowspan="1" colspan="1">79</td><td align="char" rowspan="1" colspan="1">5 (6.3)</td></tr></tbody></table><table-wrap-foot><fn id="cac212593-tbl4-note-0001"><p>Abbreviation: NSCLC, non&#8208;small cell lung cancer.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>In patients with advanced adenocarcinoma, compared with various positive mutations, <italic toggle="yes">EGFR</italic>&#8208;negative (17.2%), <italic toggle="yes">BRAF</italic>&#8208;negative (8.1%), <italic toggle="yes">ROS1</italic>&#8208;negative (7.7%), and <italic toggle="yes">MET</italic>&#8208;negative (7.5%) tumors had more frequent <italic toggle="yes">ALK</italic> rearrangements, but PD&#8208;L1&#8208;negative tumors had fewest <italic toggle="yes">ALK</italic> rearrangements. The <italic toggle="yes">ALK</italic> gene rearrangement was more frequently seen with <italic toggle="yes">ROS1</italic> (4.3%), <italic toggle="yes">MET</italic> (2.5%), <italic toggle="yes">RET</italic> (2.2%), <italic toggle="yes">ERBB2</italic> (1.9%), <italic toggle="yes">KRAS</italic> (1.2%), <italic toggle="yes">BRAF</italic> (0.9%), and <italic toggle="yes">EGFR</italic> mutations (0.6%) than other mutations in advanced adenocarcinoma.</p></sec><sec id="cac212593-sec-0160"><label>3.5</label><title>Mutation&#8208;positive rates in subgroups of patients with advanced adenocarcinoma</title><p>Table&#160;<xref rid="cac212593-tbl-0005" ref-type="table">5</xref> presents the positive rates of driver genes in different subgroups of patients with advanced adenocarcinoma. The <italic toggle="yes">ALK</italic>&#8208;positive<italic toggle="yes">ALK</italic> gene rearrangement rate was higher in females (9.4%) than in males (6.8%). The <italic toggle="yes">EGFR</italic>&#8208;positive tumors were higher in females (66.5%) and mainly in never smokers of different age groups. Three hundred and seventy&#8208;five males out of 2,609 (14.4%) had <italic toggle="yes">KRAS</italic> mutation, and 99 females out of 2,492 (4.0%) were <italic toggle="yes">KRAS</italic> mutation, predominantly current smokers aged &gt; 35 years. Additionally, the <italic toggle="yes">BRAF, ERBB2, MET, RET</italic>, and <italic toggle="yes">ROS1</italic> positive rates were 1.7%, 3.0%, 3.3%, 1.5%, and 2.0% in males and 1.6%, 3.1%, 2.0%, 1.2%, and 3.0% in females. The results showed that 74.3% of male patients and 90.8% of female patients had mutations in at least one of these eight driver genes, making them potential candidates for targeted drugs.</p><table-wrap position="float" id="cac212593-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Incidence of mutations in patients with advanced adenocarcinoma with known status of smoking.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="6" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Age (years) and smoking status</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">&#8804; 35</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">36&#8208;65</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">&gt; 65</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Mutated gene</th><th align="left" rowspan="1" colspan="1">Mutated rate</th><th align="left" rowspan="1" colspan="1">Never</th><th align="left" rowspan="1" colspan="1">Current</th><th align="left" rowspan="1" colspan="1">Never</th><th align="left" rowspan="1" colspan="1">Current</th><th align="left" rowspan="1" colspan="1">Never</th><th align="left" rowspan="1" colspan="1">Current</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">ALK</italic>
</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">6.8% (456/6,681)</td><td align="char" rowspan="1" colspan="1">37.7% (23/61)</td><td align="char" rowspan="1" colspan="1">46.2% (18/39)</td><td align="char" rowspan="1" colspan="1">10.3% (169/1,635)</td><td align="char" rowspan="1" colspan="1">6.7% (171/2,541)</td><td align="char" rowspan="1" colspan="1">4.0% (38/942)</td><td align="char" rowspan="1" colspan="1">2.5% (37/1,463)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">9.4% (564/5,974)</td><td align="char" rowspan="1" colspan="1">33.9% (42/124)</td><td align="char" rowspan="1" colspan="1">0 (0/2)</td><td align="char" rowspan="1" colspan="1">11.3% (430/3,796)</td><td align="char" rowspan="1" colspan="1">8.2% (8/98)</td><td align="char" rowspan="1" colspan="1">4.3% (80/1,874)</td><td align="char" rowspan="1" colspan="1">5.0% (4/80)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>BRAF</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">1.7% (42/2,525)</td><td align="char" rowspan="1" colspan="1">0 (0/21)</td><td align="char" rowspan="1" colspan="1">0 (0/14)</td><td align="char" rowspan="1" colspan="1">1.6% (10/626)</td><td align="char" rowspan="1" colspan="1">1.4% (13/961)</td><td align="char" rowspan="1" colspan="1">1.2% (4/332)</td><td align="char" rowspan="1" colspan="1">2.6% (15/571)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">1.6% (39/2,431)</td><td align="char" rowspan="1" colspan="1">4.3% (2/47)</td><td align="char" rowspan="1" colspan="1">0 (0/0)</td><td align="char" rowspan="1" colspan="1">1.3% (21/1,559)</td><td align="char" rowspan="1" colspan="1">2.1% (1/47)</td><td align="char" rowspan="1" colspan="1">2.0% (15/755)</td><td align="char" rowspan="1" colspan="1">0 (0/23)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>EGFR</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">41.6% (1,521/3,659)</td><td align="char" rowspan="1" colspan="1">34.5% (10/29)</td><td align="char" rowspan="1" colspan="1">30.4% (7/23)</td><td align="char" rowspan="1" colspan="1">51.3% (434/846)</td><td align="char" rowspan="1" colspan="1">37.2% (547/1,471)</td><td align="char" rowspan="1" colspan="1">50.4% (231/458)</td><td align="char" rowspan="1" colspan="1">35.1% (292/832)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">66.5% (2,332/3,505)</td><td align="char" rowspan="1" colspan="1">35.8% (24/67)</td><td align="char" rowspan="1" colspan="1">0 (0/1)</td><td align="char" rowspan="1" colspan="1">66.1% (1,504/2,275)</td><td align="char" rowspan="1" colspan="1">61.4% (35/57)</td><td align="char" rowspan="1" colspan="1">70.1% (751/1,071)</td><td align="char" rowspan="1" colspan="1">52.9% (18/34)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ERBB2</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">3.0% (54/1,817)</td><td align="char" rowspan="1" colspan="1">7.7% (1/13)</td><td align="char" rowspan="1" colspan="1">0 (0/11)</td><td align="char" rowspan="1" colspan="1">2.6% (11/422)</td><td align="char" rowspan="1" colspan="1">2.7% (20/731)</td><td align="char" rowspan="1" colspan="1">3.7% (9/224)</td><td align="char" rowspan="1" colspan="1">3.1% (13/416)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">3.1% (54/1,734)</td><td align="char" rowspan="1" colspan="1">0 (0/30)</td><td align="char" rowspan="1" colspan="1">0 (0/0)</td><td align="char" rowspan="1" colspan="1">2.6% (29/1,112)</td><td align="char" rowspan="1" colspan="1">2.8% (1/36)</td><td align="char" rowspan="1" colspan="1">4.5% (24/537)</td><td align="char" rowspan="1" colspan="1">0 (0/19)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>KRAS</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">14.4% (375/2,609)</td><td align="char" rowspan="1" colspan="1">4.8% (1/21)</td><td align="char" rowspan="1" colspan="1">0 (0/16)</td><td align="char" rowspan="1" colspan="1">9.4% (60/640)</td><td align="char" rowspan="1" colspan="1">18.5% (186/1,008)</td><td align="char" rowspan="1" colspan="1">10.1% (34/338)</td><td align="char" rowspan="1" colspan="1">16.0% (94/586)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">4.0% (99/2,492)</td><td align="char" rowspan="1" colspan="1">0 (0/47)</td><td align="char" rowspan="1" colspan="1">0 (0/0)</td><td align="char" rowspan="1" colspan="1">3.9% (63/1,600)</td><td align="char" rowspan="1" colspan="1">6.0% (3/50)</td><td align="char" rowspan="1" colspan="1">3.8% (29/772)</td><td align="char" rowspan="1" colspan="1">17.4% (4/23)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MET</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">3.3% (59/1,797)</td><td align="char" rowspan="1" colspan="1">0 (0/13)</td><td align="char" rowspan="1" colspan="1">8.3% (1/12)</td><td align="char" rowspan="1" colspan="1">3.7% (15/410)</td><td align="char" rowspan="1" colspan="1">2.9% (21/731)</td><td align="char" rowspan="1" colspan="1">3.9% (8/203)</td><td align="char" rowspan="1" colspan="1">3.3% (14/428)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">2.0% (33/1,684)</td><td align="char" rowspan="1" colspan="1">3.1% (1/32)</td><td align="char" rowspan="1" colspan="1">0 (0/0)</td><td align="char" rowspan="1" colspan="1">1.8% (19/1,062)</td><td align="char" rowspan="1" colspan="1">0 (0/37)</td><td align="char" rowspan="1" colspan="1">2.3% (12/530)</td><td align="char" rowspan="1" colspan="1">4.3% (1/23)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RET</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">1.5% (33/2,180)</td><td align="char" rowspan="1" colspan="1">0 (0/16)</td><td align="char" rowspan="1" colspan="1">7.7% (1/13)</td><td align="char" rowspan="1" colspan="1">3.4% (18/536)</td><td align="char" rowspan="1" colspan="1">1.1% (9/805)</td><td align="char" rowspan="1" colspan="1">0.6% (2/311)</td><td align="char" rowspan="1" colspan="1">0.6% (3/499)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">1.2% (25/2,019)</td><td align="char" rowspan="1" colspan="1">0 (0/31)</td><td align="char" rowspan="1" colspan="1">0 (0/1)</td><td align="char" rowspan="1" colspan="1">1.6% (20/1,267)</td><td align="char" rowspan="1" colspan="1">2.6% (1/39)</td><td align="char" rowspan="1" colspan="1">0.6% (4/659)</td><td align="char" rowspan="1" colspan="1">0 (0/22)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ROS1</bold>
</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="char" rowspan="1" colspan="1">2.0% (74/3,659)</td><td align="char" rowspan="1" colspan="1">11.1% (4/36)</td><td align="char" rowspan="1" colspan="1">0 (0/20)</td><td align="char" rowspan="1" colspan="1">2.6% (24/928)</td><td align="char" rowspan="1" colspan="1">2.5% (33/1,322)</td><td align="char" rowspan="1" colspan="1">1.5% (8/551)</td><td align="char" rowspan="1" colspan="1">0.6% (5/802)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="char" rowspan="1" colspan="1">3.0% (103/3,385)</td><td align="char" rowspan="1" colspan="1">7.7% (5/65)</td><td align="char" rowspan="1" colspan="1">100% (1/1)</td><td align="char" rowspan="1" colspan="1">3.0% (64/2,103)</td><td align="char" rowspan="1" colspan="1">8.0% (4/50)</td><td align="char" rowspan="1" colspan="1">2.6% (29/1,132)</td><td align="char" rowspan="1" colspan="1">0 (0/34)</td></tr></tbody></table><table-wrap-foot><fn id="cac212593-tbl5-note-0001"><p>
<italic toggle="yes">Note</italic>: *Patients with unknown history of smoking (<italic toggle="yes">n</italic> = 4781) were excluded from this analysis.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="cac212593-sec-0170"><label>4</label><title>DISCUSSION</title><p>This retrospective study aimed to comprehensively understand the current status and quality control of <italic toggle="yes">ALK</italic> test for lung cancer in China (the RATICAL study). The analyses included 23,689 patients with advanced NSCLC who underwent <italic toggle="yes">ALK</italic> test in 30 medical centers across China. The overall <italic toggle="yes">ALK gene rearrangement</italic> rate was 6.7% in advanced NSCLC, with higher <italic toggle="yes">ALK</italic> gene rearrangement rates in patients aged &#8804; 35 years, females, never smokers, and patients with adenocarcinoma. The IHC&#8208;VENTANA&#8208;D5F3 was used to test the <italic toggle="yes">ALK</italic> gene rearrangements most frequently. The largest number of samples tested were histological samples.</p><p>The overall <italic toggle="yes">ALK</italic> gene rearrangement rate was 6.7% in advanced NSCLC in the present study. This outcome was consistent with that of the previous studies from China (6.6% [<xref rid="cac212593-bib-0009" ref-type="bibr">9</xref>] and 4%&#8208;11.6% [<xref rid="cac212593-bib-0019" ref-type="bibr">19</xref>]). Notably, these rates are higher compared to those observed in Western populations, underscoring potential ethnic and regional variations in genetic susceptibility to <italic toggle="yes">ALK</italic> rearrangements. For example, a study reported that Asian patients exhibited a significantly higher prevalence of <italic toggle="yes">ALK</italic> gene rearrangement disease at 22.0%, compared to New Zealand Europeans at 4.4% [<xref rid="cac212593-bib-0020" ref-type="bibr">20</xref>]. This suggests that genetic factors may contribute to the higher incidence of <italic toggle="yes">ALK</italic> rearrangements in Asian populations. The <italic toggle="yes">ALK</italic> gene rearrangement rates were 31.9%, 8.4%, and 3.0% for patients aged &#8804; 35, 36&#8208;65, and &gt; 65 years in advanced NSCLC in the present study, respectively. The <italic toggle="yes">ALK</italic> gene rearrangement rate was 8.3% for advanced NSCLC patients who never smoked, which was higher than for patients who smoked or were smoking (4.2%). The positive detection rate among women was 9.0%, higher than 5.2% among men in the present study. These results were consistent with those from a previous study [<xref rid="cac212593-bib-0010" ref-type="bibr">10</xref>]. The <italic toggle="yes">ALK</italic> gene rearrangement rate was 8.2% for patients with advanced lung adenocarcinoma, numerically higher than that in patients with advanced NSCLC, indicating a lower positive rate in patients with non&#8208;adenocarcinoma. Despite this outcome, several squamous cell carcinoma patients with <italic toggle="yes">ALK</italic> gene rearrangement have benefitted from <italic toggle="yes">ALK</italic> inhibitors [<xref rid="cac212593-bib-0016" ref-type="bibr">16</xref>]. Therefore, Chinese clinical experts recommend <italic toggle="yes">ALK</italic> test for patients with advanced NSCLC (non&#8208;adenocarcinoma) to make better decisions on treatment options [<xref rid="cac212593-bib-0021" ref-type="bibr">21</xref>].</p><p>The diagnostic guidelines strongly recommend the IHC&#8208;VENTANA&#8208;D5F3, FISH, RT&#8208;PCR, and NGS methods for detecting the <italic toggle="yes">ALK</italic> fusion gene [<xref rid="cac212593-bib-0017" ref-type="bibr">17</xref>]. Each method has distinct advantages: FISH is highly specific but may have false&#8208;negative issues; IHC&#8208;VENTANA&#8208;D5F3 offers quick screening with high sensitivity; RT&#8208;PCR excels in sensitivity for known variants; and NGS not only detects known <italic toggle="yes">ALK</italic> rearrangements but also identifies concurrent genomic alterations that may impact therapy outcomes [<xref rid="cac212593-bib-0017" ref-type="bibr">17</xref>]. For instance, NGS has shown potential in predicting better disease control and longer progression&#8208;free survival in crizotinib&#8208;treated patients [<xref rid="cac212593-bib-0022" ref-type="bibr">22</xref>]. This highlights the importance of selecting appropriate diagnostic techniques based on clinical needs and available resources. The IHC methods are commonly used in clinical practice to determine <italic toggle="yes">ALK</italic> fusions because they are simple, fast, and cost&#8208;effective. Four <italic toggle="yes">ALK</italic> antibodies, such as IHC&#8208;VENTANA&#8208;D5F3, <italic toggle="yes">ALK</italic>1, 5A4, and 1A4, are presently available. Among them, <italic toggle="yes">ALK</italic>1 is less sensitive, 1A4 is less specific, and 5A4 has an unclear cut&#8208;off value [<xref rid="cac212593-bib-0023" ref-type="bibr">23</xref>]. Therefore, the IHC&#8208;VENTANA&#8208;D5F3 is the preferred choice for IHC due to its high sensitivity and specificity [<xref rid="cac212593-bib-0024" ref-type="bibr">24</xref>], and it was used in more than half of the samples analyzed in the present study. However, this test can give false&#8208;positive results when non&#8208;adenocarcinoma samples are used, warranting experienced pathologists for interpretation [<xref rid="cac212593-bib-0024" ref-type="bibr">24</xref>]. In the previously published first quality control analysis of the RATICAL study, 31 pathologists from 31 nationwide medical centers were selected to read 109 IHC sections. Only 19.4% of the pathologists were 100% accurate in the diagnosis. The false negative rate was 26.5%, positive cases were read as negative by at least one pathologist, and 41.7% of the 60 negative cases were read as positive (false positive) by at least one pathologist. The inconclusive interpretation was 31.2% [<xref rid="cac212593-bib-0018" ref-type="bibr">18</xref>]. These results highly emphasized the heterogeneity in viewing and interpretation among the pathologists on IHC slides, contributing to the variations in <italic toggle="yes">ALK</italic> gene rearrangement results observed in the present study. Consequently, guidelines have been issued in China to standardize the <italic toggle="yes">ALK</italic> test and recommend other retesting methods when the IHC&#8208;VENTANA&#8208;D5F3 results are inconclusive [<xref rid="cac212593-bib-0017" ref-type="bibr">17</xref>, <xref rid="cac212593-bib-0021" ref-type="bibr">21</xref>].</p><p>In this study, 651 patients whose sample underwent testing using the IHC&#8208;VENTANA&#8208;D5F3 protocol had a concordance rate of 99.2% in the inter&#8208;hospital agreement analysis, and 119 samples who underwent testing using other protocols (PCR, NGS, FISH, and IHC) were reviewed by the IHC&#8208;VENTANA&#8208;D5F3 and resulted in a concordance rate of 93.2%. In addition, the agreement of detection of different methods specifically for those validated cases confirmed by FISH were 98.0% for IHC&#8208;VENTANA&#8208;D5F3, 98.7% for NGS, and 91.3% for RT&#8208;PCR, showing a high concordance rate with the initial tests, but some inconsistencies remained. Indeed, the concordance rate between IHC and RT&#8208;PCR was relatively low at 91.3%. This may be attributed to the specificity of RT&#8208;PCR, which can lead to false negatives if the specific ALK fusion sequences are not present. Additionally, the potential for IHC to produce false positive results [<xref rid="cac212593-bib-0017" ref-type="bibr">17</xref>], contributes to these discordances. Furthermore, due to the small sample size of discordances, the detailed analysis to track possible reasons is infeasible. In a previous study of <italic toggle="yes">ALK</italic> test in over 3,000 NSCLC patients, FISH and IHC&#8208;VENTANA&#8208;D5F3 were used. As a result, 14 patients were read as negative by FISH and positive by IHC but further validated as <italic toggle="yes">ALK</italic> gene rearrangement by NGS [<xref rid="cac212593-bib-0012" ref-type="bibr">12</xref>]. Therefore, when inconsistencies arise with different test methods, clinicians and pathologists should discuss them to reach a consensus [<xref rid="cac212593-bib-0017" ref-type="bibr">17</xref>].</p><p>Regarding selecting specimens for downstream test, tumor tissue samples are highly recommended. When tumor tissue specimens do not meet the requirements or are unavailable, cytology samples can be used. In a few circumstances of advanced lung cancer, when tissue or cytology samples are objectively unavailable, blood or cerebrospinal fluid was used for the diagnosis [<xref rid="cac212593-bib-0021" ref-type="bibr">21</xref>]. In this study, most (more than 80%) of <italic toggle="yes">ALK</italic> tests were performed on histological samples in clinical practice, followed by cytological samples. Only a few evaluations were performed using body fluid samples. However, a previous study found that the <italic toggle="yes">ALK</italic> test on cytological specimens was reliable and sensitive [<xref rid="cac212593-bib-0025" ref-type="bibr">25</xref>]. In the present study, about 20% of patients were tested with samples obtained from metastatic foci. While our study observed a higher <italic toggle="yes">ALK</italic> gene rearrangement rate in metastatic tumors compared to primary lesions, it is important to recognize that the underlying <italic toggle="yes">ALK</italic> gene rearrangement status remains consistent between primary and metastatic sites. This consistency supports the reliability of using either primary or metastatic tissue samples for detecting <italic toggle="yes">ALK</italic> rearrangements. The literature corroborates this, showing high concordance of <italic toggle="yes">ALK</italic> gene rearrangements in both tumor sites, which validates the use of metastatic samples in clinical diagnostic settings when primary tumor tissue is not available [<xref rid="cac212593-bib-0026" ref-type="bibr">26</xref>, <xref rid="cac212593-bib-0027" ref-type="bibr">27</xref>].</p><p>We also analyzed for other driver genes or biomarkers concurrently with <italic toggle="yes">ALK</italic> gene rearrangement detection and found a small number of cases of mutations, except for high co&#8208;positivity with PD&#8208;L1. The co&#8208;occurrence of <italic toggle="yes">ALK</italic> gene rearrangement and mutations in other driver genes was rare, as supported by the literature [<xref rid="cac212593-bib-0028" ref-type="bibr">28</xref>], except for the <italic toggle="yes">TP53</italic> mutation [<xref rid="cac212593-bib-0029" ref-type="bibr">29</xref>], which was not assessed in the present study. RT&#8208;PCR or NGS test is recommended when <italic toggle="yes">ALK</italic> gene rearrangement and other driver gene mutations are considered [<xref rid="cac212593-bib-0017" ref-type="bibr">17</xref>]. Since co&#8208;occurrence of mutations is rare, the treatment options are uncertain [<xref rid="cac212593-bib-0030" ref-type="bibr">30</xref>, <xref rid="cac212593-bib-0031" ref-type="bibr">31</xref>, <xref rid="cac212593-bib-0032" ref-type="bibr">32</xref>]. Notably, <italic toggle="yes">EGFR</italic> mutation was more common in women, and <italic toggle="yes">KRAS</italic> mutation was more common in males, as supported by the literature [<xref rid="cac212593-bib-0033" ref-type="bibr">33</xref>, <xref rid="cac212593-bib-0034" ref-type="bibr">34</xref>].</p><p>
<italic toggle="yes">ALK</italic> test is available in China by IHC and FISH (these methods only target the ALK gene or protein, and therefore, not all patients have EGFR test), but also by RT&#8208;PCR and NGS assays that include <italic toggle="yes">ALK</italic> and multiple other genes (as listed in Tables&#160;<xref rid="cac212593-tbl-0004" ref-type="table">4</xref>, <xref rid="cac212593-tbl-0005" ref-type="table">5</xref>). Therefore, the results for these genes are also available when NGS and RT&#8208;PCR assays are performed. The results were generally consistent with the mutation rates of these driver genes reported in the literature without new signals [<xref rid="cac212593-bib-0035" ref-type="bibr">35</xref>, <xref rid="cac212593-bib-0036" ref-type="bibr">36</xref>, <xref rid="cac212593-bib-0037" ref-type="bibr">37</xref>].</p><p>In managing advanced NSCLC, comprehensive molecular profiling that includes not only <italic toggle="yes">ALK</italic> but also <italic toggle="yes">ROS1, RET, NTRK</italic>, and other actionable gene fusions is critical. However, the practical limitations of conventional methods like <italic toggle="yes">ALK</italic> IHC necessitate the use of more advanced techniques. At our institution, we have established a versatile diagnostic model that integrates multiple test platforms to accommodate the variable quality of clinical biopsy specimens. When tissue NGS is not feasible due to sample quality issues, we employ ARMS&#8208;PCR+IHC/FISH or switch to blood ctDNA NGS test, which allows us to continue detecting driver gene variants despite the challenges [<xref rid="cac212593-bib-0038" ref-type="bibr">38</xref>]. This strategic approach ensures that comprehensive genomic profiling can be achieved, supporting the use of targeted therapies based on a broad spectrum of detected mutations, including common and rare gene loci. Our experiences emphasize the importance of a flexible, multi&#8208;platform test strategy to overcome the limitations of tissue sample quality and ensure that molecular diagnostics can inform effective treatment planning for all patients.</p><p>This study had some limitations. First, <italic toggle="yes">ALK</italic> test was based on the clinical reality of each participating hospital. Each hospital might have different test protocols to match their local equipment, hardware, software, and the pathologists' preferences. Nevertheless, the quality control principles are national and were uniformly applied by all centers. Second, it was a cross&#8208;sectional study, and the treatment of patients with <italic toggle="yes">ALK</italic> gene rearrangement (e.g., treatment with <italic toggle="yes">ALK</italic> inhibitors) was not followed. Third, missing data might have occurred due to the large sample size. Fourth, our study included data from 30 centers across the country, but the standards of <italic toggle="yes">ALK</italic> test and the testers' experience might have varied from center to center. Fifth, only nine of the 30 centers were performing NGS. Since biopsies provided limited specimens used primarily for histology, immunohistochemistry, and basic genetic test, insufficient material was often left for NGS. Nevertheless, multiple quality controls were performed at all centers to minimize the impact of this bias on the outcomes. Besides, while this study provides comprehensive insights into the test patterns and positivity rates of ALK rearrangements, it does not include clinical outcome data such as overall survival.</p><p>In conclusion, we investigated <italic toggle="yes">ALK</italic> gene rearrangement rates and test patterns in China through this real&#8208;world study. The overall <italic toggle="yes">ALK</italic> gene rearrangement rate among advanced NSCLC in China was 6.7%, while advanced NSCLC patients with <italic toggle="yes">ALK</italic> gene rearrangement had specific clinicopathological characteristics. The IHC&#8208;VENTANA&#8208;D5F3 was used most frequently for detecting the <italic toggle="yes">ALK</italic> gene rearrangement with high consistency. This study provides a basis for detecting <italic toggle="yes">ALK</italic> gene rearrangements in patients with NSCLC, aiming to optimize future <italic toggle="yes">ALK</italic> gene rearrangement test patterns in patients with NSCLC.</p></sec><sec id="cac212593-sec-0180"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Lin Li</bold>: Data curation; formal analysis; writing&#8212;original draft. <bold>Lei Guo</bold>: Data curation; project administration. <bold>Wencai Li, Chunyan Wu, Yanfeng Xi, Yuan Ji, Lili Jiang, Ji Li, Jingping Yun, Gang Chen, Yuan Li, Yueping Liu, Dianbin Mu, Yuchen Han, Leina Sun, Qingxin Xia, Xiaodong Teng, Nanying Che, Wei Wu, Xueshan Qiu, Chao Liu, Xiaochu Yan, Daiqiang Li, Zhihong Zhang, Zhe Wang, Yujun Li, Zheng Wang, Lingchuan Guo, Xiu Nie, Jingshu Geng and Jianhua Zhou</bold>: Data curation; project administration; supervision. <bold>Jianming Ying</bold>: Conceptualization; methodology; funding acquisition; supervision; formal analysis; writing&#8212;review &amp; editing.</p></sec><sec sec-type="COI-statement" id="cac212593-sec-0200"><title>CONFLICT OF INTEREST STATEMENT</title><p>All authors declare no competing interests.</p></sec><sec id="cac212593-sec-0230"><title>ETHICS APPROVAL AND CONSENT TO PARTICIPATE</title><p>This retrospective study was approved by the Ethics Committee of the Cancer Hospital of the Chinese Academy of Medical Sciences and reported to the Ethics Committee of all study centers. Informed consent was obtained from all patients.</p></sec><sec id="cac212593-sec-0240"><title>PATIENT CONSENT STATEMENT</title><p>Informed consent was obtained from the patients.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cac212593-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAC2-44-992-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cac212593-sec-0190"><title>ACKNOWLEDGEMENTS</title><p>We would like to thank Genowis (Beijing) Gene Technology Co., Ltd. for undertaking data analysis tasks in the project. This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) (grant no. 2021&#8208;1&#8208;I2M&#8208;012 and 2022&#8208;I2M&#8208;C&amp;T&#8208;B&#8208;078), Beijing Hope Run Special Fund of Cancer Foundation of the People's Republic of China (grant no. LC2019L04), National Key Research and Development Program (grant no. 2022YFC2409902) and Capital's Funds for Health Improvement and Research (grant no. 2020&#8208;2Z&#8208;4028). They had no role in study design, in the collection, analysis, and interpretation of data; in the report's writing; or in the decision to submit the article for publication.</p></ack><sec sec-type="data-availability" id="cac212593-sec-0220"><title>DATA AVAILABILITY STATEMENT</title><p>The data supporting the findings of this study are available within the article and its Supplementary Materials.</p></sec><ref-list id="cac212593-bibl-0001"><title>REFERENCES</title><ref id="cac212593-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cac212593-cit-0001"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Incidence and mortality of lung cancer in China, 2008&#8208;2012</article-title>. <source>Chin J Cancer Res</source>. <year>2018</year>;<volume>30</volume>(<issue>6</issue>):<fpage>580</fpage>&#8211;<lpage>587</lpage>.<pub-id pub-id-type="pmid">30700926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21147/j.issn.1000-9604.2018.06.02</pub-id><pub-id pub-id-type="pmcid">PMC6328502</pub-id></mixed-citation></ref><ref id="cac212593-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cac212593-cit-0002"><string-name name-style="western"><surname>Thai</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Sequist</surname><given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Gainor</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Heist</surname><given-names>RS</given-names></string-name>. <article-title>Lung cancer</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>398</volume>(<issue>10299</issue>):<fpage>535</fpage>&#8211;<lpage>554</lpage>.<pub-id pub-id-type="pmid">34273294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00312-3</pub-id></mixed-citation></ref><ref id="cac212593-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cac212593-cit-0003"><string-name name-style="western"><surname>Sung</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Jemal</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>. <source>CA Cancer J Clin</source>. <year>2021</year>;<volume>71</volume>(<issue>3</issue>):<fpage>209</fpage>&#8208;<lpage>249</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></ref><ref id="cac212593-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cac212593-cit-0004"><string-name name-style="western"><surname>Shokoohi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Hashami</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pender</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Effect of targeted therapy and immunotherapy on advanced nonsmall&#8208;cell lung cancer outcomes in the real world</article-title>. <source>Cancer Med</source>. <year>2022</year>;<volume>11</volume>(<issue>1</issue>):<fpage>86</fpage>&#8208;<lpage>93</lpage>.<pub-id pub-id-type="pmid">34786889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.4427</pub-id><pub-id pub-id-type="pmcid">PMC8704182</pub-id></mixed-citation></ref><ref id="cac212593-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cac212593-cit-0005"><string-name name-style="western"><surname>Seegobin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Majeed</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Wiest</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Manochakian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>. <article-title>Immunotherapy in Non&#8208;Small Cell Lung Cancer With Actionable Mutations Other Than EGFR</article-title>. <source>Front Oncol</source>. <year>2021</year>;<volume>11</volume>:<elocation-id>750657</elocation-id>.<pub-id pub-id-type="pmid">34926258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.750657</pub-id><pub-id pub-id-type="pmcid">PMC8671626</pub-id></mixed-citation></ref><ref id="cac212593-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cac212593-cit-0006"><string-name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>. <article-title>Therapeutic advances in non&#8208;small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy</article-title>. <source>MedComm (2020)</source>. <year>2021</year>;<volume>2</volume>(<issue>4</issue>):<fpage>692</fpage>&#8208;<lpage>729</lpage>.<pub-id pub-id-type="pmid">34977873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mco2.105</pub-id><pub-id pub-id-type="pmcid">PMC8706764</pub-id></mixed-citation></ref><ref id="cac212593-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cac212593-cit-0007"><string-name name-style="western"><surname>Du</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Tai</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>HJ</given-names></string-name>. <article-title>ALK&#8208;rearrangement in non&#8208;small&#8208;cell lung cancer (NSCLC)</article-title>. <source>Thorac Cancer</source>. <year>2018</year>;<volume>9</volume>(<issue>4</issue>):<fpage>423</fpage>&#8208;<lpage>430</lpage>.<pub-id pub-id-type="pmid">29488330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1759-7714.12613</pub-id><pub-id pub-id-type="pmcid">PMC5879058</pub-id></mixed-citation></ref><ref id="cac212593-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cac212593-cit-0008"><string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>JH</given-names></string-name>. <article-title>Overview of clinicopathologic features of ALK&#8208;rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement</article-title>. <source>Transl Lung Cancer Res</source>. <year>2015</year>;<volume>4</volume>(<issue>2</issue>):<fpage>149</fpage>&#8208;<lpage>155</lpage>.<pub-id pub-id-type="pmid">25870797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3978/j.issn.2218-6751.2014.12.02</pub-id><pub-id pub-id-type="pmcid">PMC4384218</pub-id></mixed-citation></ref><ref id="cac212593-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cac212593-cit-0009"><string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Detection of ALK translocation in non&#8208;small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single&#8208;center large&#8208;scale investigation of 1, 504 Chinese Han patients</article-title>. <source>Chin J Cancer Res</source>. <year>2016</year>;<volume>28</volume>(<issue>5</issue>):<fpage>495</fpage>&#8208;<lpage>502</lpage>.<pub-id pub-id-type="pmid">27877008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21147/j.issn.1000-9604.2016.05.04</pub-id><pub-id pub-id-type="pmcid">PMC5101223</pub-id></mixed-citation></ref><ref id="cac212593-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cac212593-cit-0010"><string-name name-style="western"><surname>Shaw</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Yeap</surname><given-names>BY</given-names></string-name>, <string-name name-style="western"><surname>Mino&#8208;Kenudson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Digumarthy</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Costa</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Heist</surname><given-names>RS</given-names></string-name>, et&#160;al. <article-title>Clinical features and outcome of patients with non&#8208;small&#8208;cell lung cancer who harbor EML4&#8208;ALK</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>26</issue>):<fpage>4247</fpage>&#8208;<lpage>4253</lpage>.<pub-id pub-id-type="pmid">19667264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.22.6993</pub-id><pub-id pub-id-type="pmcid">PMC2744268</pub-id></mixed-citation></ref><ref id="cac212593-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cac212593-cit-0011"><string-name name-style="western"><surname>Camidge</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Dziadziuszko</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mok</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Noe</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nowicka</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Updated Efficacy and Safety Data and Impact of the EML4&#8208;ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK&#8208;Positive Advanced Non&#8208;Small Cell Lung Cancer in the Global Phase III ALEX Study</article-title>. <source>J Thorac Oncol</source>. <year>2019</year>;<volume>14</volume>(<issue>7</issue>):<fpage>1233</fpage>&#8208;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">30902613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2019.03.007</pub-id></mixed-citation></ref><ref id="cac212593-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cac212593-cit-0012"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chuai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>J</given-names></string-name>. <article-title>Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment</article-title>. <source>J Thorac Oncol</source>. <year>2017</year>;<volume>12</volume>(<issue>1</issue>):<fpage>94</fpage>&#8208;<lpage>101</lpage>.<pub-id pub-id-type="pmid">27614248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2016.08.145</pub-id></mixed-citation></ref><ref id="cac212593-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cac212593-cit-0013"><string-name name-style="western"><surname>Ou</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>VW</given-names></string-name>, <string-name name-style="western"><surname>Nagasaka</surname><given-names>M</given-names></string-name>. <article-title>Catalog of 5' Fusion Partners in ALK&#8208;positive NSCLC Circa 2020</article-title>. <source>JTO Clin Res Rep</source>. <year>2020</year>;<volume>1</volume>(<issue>1</issue>):<elocation-id>100015</elocation-id>.<pub-id pub-id-type="pmid">34589917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtocrr.2020.100015</pub-id><pub-id pub-id-type="pmcid">PMC8474466</pub-id></mixed-citation></ref><ref id="cac212593-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cac212593-cit-0014"><string-name name-style="western"><surname>Solomon</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Mok</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Nakagawa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mekhail</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>First&#8208;line crizotinib versus chemotherapy in ALK&#8208;positive lung cancer</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>(<issue>23</issue>):<fpage>2167</fpage>&#8208;<lpage>2177</lpage>.<pub-id pub-id-type="pmid">25470694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1408440</pub-id></mixed-citation></ref><ref id="cac212593-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cac212593-cit-0015"><string-name name-style="western"><surname>Hida</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nokihara</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kondo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Azuma</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Seto</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Alectinib versus crizotinib in patients with ALK&#8208;positive non&#8208;small&#8208;cell lung cancer (J&#8208;ALEX): an open&#8208;label, randomised phase 3 trial</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>390</volume>(<issue>10089</issue>):<fpage>29</fpage>&#8208;<lpage>39</lpage>.<pub-id pub-id-type="pmid">28501140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)30565-2</pub-id></mixed-citation></ref><ref id="cac212593-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cac212593-cit-0016"><string-name name-style="western"><surname>Vergne</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Quere</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Andrieu&#8208;Key</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Descourt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Quintin&#8208;Roue</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Talagas</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>ALK&#8208;rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non&#8208;small cell lung cancer?</article-title><source>Lung Cancer</source>. <year>2016</year>;<volume>91</volume>:<fpage>67</fpage>&#8208;<lpage>69</lpage>.<pub-id pub-id-type="pmid">26603857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2015.11.010</pub-id></mixed-citation></ref><ref id="cac212593-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cac212593-cit-0017"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Guidelines for clinical practice of ALK fusion detection in non&#8208;small&#8208;cell lung cancer: a proposal from the Chinese RATICAL study group</article-title>. <source>J Nat Cancet Center</source>. <year>2021</year>;<volume>1</volume>(<issue>4</issue>):<fpage>123</fpage>&#8208;<lpage>131</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jncc.2021.07.005</pub-id><pub-id pub-id-type="pmcid">PMC11256616</pub-id><pub-id pub-id-type="pmid">39036803</pub-id></mixed-citation></ref><ref id="cac212593-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cac212593-cit-0018"><string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>WY</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>QX</given-names></string-name>, et&#160;al. <article-title>[Consistency of ALK Ventana&#8208;D5F3 immunohistochemistry interpretation in lung adenocarcinoma among Chinese histopathologists]</article-title>. <source>Zhonghua Bing Li Xue Za Zhi</source>. <year>2019</year>;<volume>48</volume>(<issue>12</issue>):<fpage>921</fpage>&#8208;<lpage>927</lpage>.<pub-id pub-id-type="pmid">31818064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3760/cma.j.issn.0529-5807.2019.12.002</pub-id></mixed-citation></ref><ref id="cac212593-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cac212593-cit-0019"><string-name name-style="western"><surname>Gou</surname><given-names>LY</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>YL</given-names></string-name>. <article-title>Prevalence of driver mutations in non&#8208;small&#8208;cell lung cancers in the People's Republic of China</article-title>. <source>Lung Cancer (Auckl)</source>. <year>2014</year>;<volume>5</volume>:<fpage>1</fpage>&#8208;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28210137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/LCTT.S40817</pub-id><pub-id pub-id-type="pmcid">PMC5217505</pub-id></mixed-citation></ref><ref id="cac212593-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cac212593-cit-0020"><string-name name-style="western"><surname>McKeage</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Tin Tin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khwaounjoo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sheath</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Dixon&#8208;McIver</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non&#8208;small&#8208;cell lung cancer in New Zealand</article-title>. <source>Intern Med J</source>. <year>2020</year>;<volume>50</volume>(<issue>6</issue>):<fpage>716</fpage>&#8208;<lpage>725</lpage>.<pub-id pub-id-type="pmid">31318119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imj.14435</pub-id></mixed-citation></ref><ref id="cac212593-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cac212593-cit-0021"><collab collab-type="authors">Experts from the Rs, Molecular Pathology Committee of Chinese Society of P</collab>
. <article-title>[Expert consensus on clinical practice of ALK fusion detection in non&#8208;small cell lung cancer in China]</article-title>. <source>Zhonghua Bing Li Xue Za Zhi</source>. <year>2019</year>;<volume>48</volume>(<issue>12</issue>):<fpage>913</fpage>&#8208;<lpage>920</lpage>.<pub-id pub-id-type="pmid">31818063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3760/cma.j.issn.0529-5807.2019.12.001</pub-id></mixed-citation></ref><ref id="cac212593-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cac212593-cit-0022"><string-name name-style="western"><surname>Lin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non&#8208;small&#8208;cell lung cancer</article-title>. <source>Lung Cancer</source>. <year>2019</year>;<volume>131</volume>:<fpage>62</fpage>&#8208;<lpage>68</lpage>.<pub-id pub-id-type="pmid">31027700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2019.03.018</pub-id></mixed-citation></ref><ref id="cac212593-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cac212593-cit-0023"><string-name name-style="western"><surname>Uruga</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mino&#8208;Kenudson</surname><given-names>M</given-names></string-name>. <article-title>ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK&#8208;positive NSCLC patients</article-title>. <source>Pharmgenomics Pers Med</source>. <year>2018</year>;<volume>11</volume>:<fpage>147</fpage>&#8208;<lpage>155</lpage>.<pub-id pub-id-type="pmid">30271189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/PGPM.S156672</pub-id><pub-id pub-id-type="pmcid">PMC6147206</pub-id></mixed-citation></ref><ref id="cac212593-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cac212593-cit-0024"><string-name name-style="western"><surname>Ying</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma</article-title>. <source>Ann Oncol</source>. <year>2013</year>;<volume>24</volume>(<issue>10</issue>):<fpage>2589</fpage>&#8208;<lpage>2593</lpage>.<pub-id pub-id-type="pmid">23904459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdt295</pub-id></mixed-citation></ref><ref id="cac212593-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cac212593-cit-0025"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Assessment of cytology based molecular analysis to guide targeted therapy in advanced non&#8208;small&#8208;cell lung cancer</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>7</issue>):<fpage>8332</fpage>&#8208;<lpage>8340</lpage>.<pub-id pub-id-type="pmid">26789109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.6671</pub-id><pub-id pub-id-type="pmcid">PMC4884996</pub-id></mixed-citation></ref><ref id="cac212593-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cac212593-cit-0026"><string-name name-style="western"><surname>Ma</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lyu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>J</given-names></string-name>. <article-title>Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<elocation-id>10961</elocation-id>.<pub-id pub-id-type="pmid">28887531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-11453-0</pub-id><pub-id pub-id-type="pmcid">PMC5591317</pub-id></mixed-citation></ref><ref id="cac212593-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cac212593-cit-0027"><string-name name-style="western"><surname>Qiu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>J</given-names></string-name>. <article-title>Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next&#8208;generation sequencing</article-title>. <source>Cancer Biol Ther</source>. <year>2020</year>;<volume>21</volume>(<issue>2</issue>):<fpage>170</fpage>&#8208;<lpage>177</lpage>.<pub-id pub-id-type="pmid">31651223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15384047.2019.1674070</pub-id><pub-id pub-id-type="pmcid">PMC7012153</pub-id></mixed-citation></ref><ref id="cac212593-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cac212593-cit-0028"><string-name name-style="western"><surname>Shin</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Kho</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>TO</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YI</given-names></string-name>, et&#160;al. <article-title>Co&#8208;alteration of EGFR mutation and ALK rearrangement in non&#8208;small cell lung cancer: Case series</article-title>. <source>Medicine (Baltimore)</source>. <year>2019</year>;<volume>98</volume>(<issue>9</issue>):<elocation-id>e14699</elocation-id>.<pub-id pub-id-type="pmid">30817606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000014699</pub-id><pub-id pub-id-type="pmcid">PMC6831261</pub-id></mixed-citation></ref><ref id="cac212593-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cac212593-cit-0029"><string-name name-style="western"><surname>Kron</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alidousty</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Scheffler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Merkelbach&#8208;Bruse</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Seidel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Riedel</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Impact of TP53 mutation status on systemic treatment outcome in ALK&#8208;rearranged non&#8208;small&#8208;cell lung cancer</article-title>. <source>Ann Oncol</source>. <year>2018</year>;<volume>29</volume>(<issue>10</issue>):<fpage>2068</fpage>&#8208;<lpage>2075</lpage>.<pub-id pub-id-type="pmid">30165392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdy333</pub-id><pub-id pub-id-type="pmcid">PMC6225899</pub-id></mixed-citation></ref><ref id="cac212593-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cac212593-cit-0030"><string-name name-style="western"><surname>Skoulidis</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Heymach</surname><given-names>JV</given-names></string-name>. <article-title>Co&#8208;occurring genomic alterations in non&#8208;small&#8208;cell lung cancer biology and therapy</article-title>. <source>Nat Rev Cancer</source>. <year>2019</year>;<volume>19</volume>(<issue>9</issue>):<fpage>495</fpage>&#8208;<lpage>509</lpage>.<pub-id pub-id-type="pmid">31406302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0179-8</pub-id><pub-id pub-id-type="pmcid">PMC7043073</pub-id></mixed-citation></ref><ref id="cac212593-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cac212593-cit-0031"><string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Co&#8208;occurring genomic alterations and immunotherapy efficacy in NSCLC</article-title>. <source>NPJ Precis Oncol</source>. <year>2022</year>;<volume>6</volume>(<issue>1</issue>):<fpage>4</fpage>.<pub-id pub-id-type="pmid">35042953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41698-021-00243-7</pub-id><pub-id pub-id-type="pmcid">PMC8766442</pub-id></mixed-citation></ref><ref id="cac212593-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cac212593-cit-0032"><string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Co&#8208;Occurring Potentially Actionable Oncogenic Drivers in Non&#8208;Small Cell Lung Cancer</article-title>. <source>Front Oncol</source>. <year>2021</year>;<volume>11</volume>:<elocation-id>665484</elocation-id>.<pub-id pub-id-type="pmid">34221980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.665484</pub-id><pub-id pub-id-type="pmcid">PMC8242190</pub-id></mixed-citation></ref><ref id="cac212593-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cac212593-cit-0033"><string-name name-style="western"><surname>Bell</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Brannigan</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Finkelstein</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Sordella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Settleman</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Increased prevalence of EGFR&#8208;mutant lung cancer in women and in East Asian populations: analysis of estrogen&#8208;related polymorphisms</article-title>. <source>Clin Cancer Res</source>. <year>2008</year>;<volume>14</volume>(<issue>13</issue>):<fpage>4079</fpage>&#8208;<lpage>4084</lpage>.<pub-id pub-id-type="pmid">18593984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-07-5030</pub-id><pub-id pub-id-type="pmcid">PMC3391698</pub-id></mixed-citation></ref><ref id="cac212593-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cac212593-cit-0034"><string-name name-style="western"><surname>Bacchi</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Ciol</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Queiroga</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Benine</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Ojopi</surname><given-names>EB</given-names></string-name>. <article-title>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</article-title>. <source>Clinics (Sao Paulo)</source>. <year>2012</year>;<volume>67</volume>(<issue>5</issue>):<fpage>419</fpage>&#8208;<lpage>424</lpage>.<pub-id pub-id-type="pmid">22666783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6061/clinics/2012(05)03</pub-id><pub-id pub-id-type="pmcid">PMC3351259</pub-id></mixed-citation></ref><ref id="cac212593-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cac212593-cit-0035"><string-name name-style="western"><surname>Chevallier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Borgeaud</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Addeo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Friedlaender</surname><given-names>A</given-names></string-name>. <article-title>Oncogenic driver mutations in non&#8208;small cell lung cancer: Past, present and future</article-title>. <source>World J Clin Oncol</source>. <year>2021</year>;<volume>12</volume>(<issue>4</issue>):<fpage>217</fpage>&#8208;<lpage>237</lpage>.<pub-id pub-id-type="pmid">33959476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v12.i4.217</pub-id><pub-id pub-id-type="pmcid">PMC8085514</pub-id></mixed-citation></ref><ref id="cac212593-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cac212593-cit-0036"><string-name name-style="western"><surname>Liu</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>YL</given-names></string-name>. <article-title>Emerging evidence and treatment paradigm of non&#8208;small cell lung cancer</article-title>. <source>J Hematol Oncol</source>. <year>2023</year>;<volume>16</volume>(<issue>1</issue>):<fpage>40</fpage>.<pub-id pub-id-type="pmid">37069698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-023-01436-2</pub-id><pub-id pub-id-type="pmcid">PMC10108547</pub-id></mixed-citation></ref><ref id="cac212593-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cac212593-cit-0037"><string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Clinical characteristics and targeted therapy of different gene fusions in non&#8208;small cell lung cancer: a narrative review</article-title>. <source>Transl Lung Cancer Res</source>. <year>2023</year>;<volume>12</volume>(<issue>4</issue>):<fpage>895</fpage>&#8208;<lpage>908</lpage>.<pub-id pub-id-type="pmid">37197619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr-22-566</pub-id><pub-id pub-id-type="pmcid">PMC10183389</pub-id></mixed-citation></ref><ref id="cac212593-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cac212593-cit-0038"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>J</given-names></string-name>. <article-title>Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients</article-title>. <source>JTO Clin Res Rep</source>. <year>2021</year>;<volume>2</volume>(<issue>5</issue>):<elocation-id>100167</elocation-id>.<pub-id pub-id-type="pmid">34590019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtocrr.2021.100167</pub-id><pub-id pub-id-type="pmcid">PMC8474491</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>